Exelixis
EXEL
#1317
Rank
NZ$30.12 B
Marketcap
NZ$123.47
Share price
-0.31%
Change (1 day)
63.83%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): NZ$6.06

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$6.26. In 2025 the company made an earnings per share (EPS) of NZ$5.23.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.0615.89%
2025NZ$5.23
2023NZ$1.1814.61%
2022NZ$1.03-22.97%
2021NZ$1.34100%
2020NZ$0.67-65.09%
2019NZ$1.92-53.91%
2018NZ$4.16333.96%
2017NZ$0.96-260.61%
2016NZ-$0.60-58.75%
2015NZ-$1.45-42.45%
2014NZ-$2.515.3%
2013NZ-$2.39

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$12.08 93.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$1.28-79.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$31.42 402.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$3.58-42.76%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$1.80-71.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$8.17 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$5.20-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$25.71-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.52-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA